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Repositionable Valved Stent for
ndovascular Treatment of Deteriorated Bioprostheses
achid Zegdi, MD, PHD,*† Ziad Khabbaz, MD,† Nicolas Borenstein, DVM,‡ Jean-Noël Fabiani, MD*†
aris, France
OBJECTIVES We report our animal experience of endovascular valve replacement (VR) of failed biopros-
thesis (BP) using an original delivery catheter allowing repositioning of the valved stent (VS).
BACKGROUND Among the different devices designed for percutaneous VR, none has the potential for
repositioning of a fully deployed VS.
METHODS Five sheep underwent, on beating heart, tricuspid VR with a stented BP. Prolapse of 1 leaflet
was induced by tearing. For the endovascular tricuspid VR, we used a VS constructed with
a nitinol self-expandable stent and a porcine stentless aortic valve. We also used an original
delivery catheter, allowing repositioning of the VS through a compression or relaxation
mechanism of the stent.
RESULTS Epicardial echocardiography and right ventriculography showed severe tricuspid regurgita-
tion, with a regurgitant jet extending to the inferior vena cava. After surgical exposure to the
infrarenal inferior vena cava, the VS was successfully implanted inside the failed BP in all
cases. Repositioning of the fully deployed VS was always possible. Echocardiographic and
macroscopic studies revealed adequate VS positioning, excellent leaflet opening, and absence
of any intraprosthetic or periprosthetic leak.
CONCLUSIONS Endovascular VR was easily performed in sheep with failed BP in the tricuspid position. The
novel delivery catheter allowed adequate repositioning of our fully deployed VS before its
definitive release. One may anticipate that the safety improvement conferred by this new
technology will certainly favor the development of percutaneous VR in clinical practice. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.017Coll Cardiol 2006;48:1365–8) © 2006 by the American College of Cardiology Foundation
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ttructural valve deterioration (SVD) is the most frequent
ong-term complication of implanted bioprosthesis (BP).
hen severe enough, reoperation may be necessary with
n increased operative risk in comparison with the first
peration (1).
Since the recent publications of percutaneous pulmonary
r aortic valve replacement (VR), the enthusiasm of the
edical community toward these potential alternatives to
urgery has been dramatically increasing (2,3). However,
ncountered problems are numerous, and there is still a long
ay before a safe and effective procedure becomes available.
A major problem encountered with percutaneous VR is
he impossibility of readjusting the position of a valved stent
VS) once fully deployed. Bad positioning of the VS could
ead to a fatal per-procedural issue (3). None of the available
S have the potential to be repositioned after complete
eployment (4). Thus, being able to reposition a fully
eployed VS could prove of crucial importance and would
ertainly favor the development of percutaneous VR by
mproving the safety of the procedure.
The present animal study had 2 main objectives: first, to
est the feasibility of the endovascular treatment of a failed
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hirurgie Cardio-Vasculaire, Hôpital Européen Georges Pompidou, Paris, France;
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ccepted July 10, 2006.P with a VS, and second, to test a novel delivery device
ermitting the repositioning of a fully deployed VS.
ETHODS
alved stent and delivery device. A 25-mm porcine aortic
tentless valve (Toronto SPV, model SPA-101-25, St. Jude
edical, Minneapolis, Minnesota) was mounted onto a
0-mm nitinol self-expandable stent. After compression,
he VS was introduced inside a 13-mm delivery catheter.
The originality of the delivery system consisted of the
ossibility of controlling precisely and reversibly the
eployment of the VS after the delivery catheter has been
etrieved. This was because of the presence of 2 sutures
ncircling the stent, whose traction through a proximal
andle could reversibly affect the state (deployed or com-
ressed) of the stent (Fig. 1). Therefore, if the location of
he deployed VS was judged unsatisfactory, the operator had
he possibility of repositioning the VS as often as necessary
efore final delivery. Once deployed in an adequate position,
he VS was definitely liberated from the delivery catheter by
ulling on a wire that controlled the attachment of the 2
utures. The delivery catheter could then be withdrawn,
eaving the VS in place.
xperimental protocol. Five sheep (50 kg) were used for
ur experiments. All of the animals were treated according
o the European regulations for animal experimentation (5).
hrough a right thoracotomy, tricuspid valve replacement
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A Repositionable Valved Stent October 3, 2006:1365–8as first performed on a beating heart with a Carpentier-
dwards Perimount number 27 aortic BP (model 2,800,
dwards Lifesciences, Irvine, California). The anterior
eaflet of the BP was cut along its 2 commissural attach-
ents to create prosthesis failure.
The infrarenal inferior vena cava was then accessed
hrough a right retroperitoneal approach. A guidewire was
nserted into the vein and passed under fluoroscopic guid-
nce into the pulmonary artery, after crossing the tricuspid
P. The VS was positioned inside the BP. The external
heath was then pulled back and the VS deployed by
eleasing the traction on the 2 encircling sutures. When
orrectly positioned, the VS was definitively released from
he delivery catheter.
valuation of the VS. After insertion of the failed BP,
ricuspid regurgitation was assessed semi-quantitatively
ith epicardial echocardiography and right ventriculogra-
hy. After implantation of the VS and using standard
cho-Doppler techniques, the transvalvular gradient was
etermined and any intraprosthetic or periprosthetic leak
as recorded. Sheep were killed 1 to 2 h after the
rocedure, and hearts were then harvested. Positioning,
Abbreviations and Acronyms
BP  bioprosthesis
SVD  structural valve deterioration
VR  valve replacement
VS  valved stentigure 1. Representation of the principle of compression-relaxation of the valved
he 2 encircling sutures. (Top, right) The stent has been reversibly deployed. (tent deformation, and leaflet movement of the VS were
arefully analyzed.
ESULTS
he experiment was completed in all 5 sheep. All animals
ere weaned from bypass without inotropic support. Dura-
ion (median time) of extracorporeal circulation was 48 mn
range 38 to 52 mn).
Intraprosthetic tricuspid insufficiency was severe in all
heep. Bidimensional echocardiography showed prolapse of
he anterior leaflet of the BP into the right atrium. The vena
ontracta width was 8 mm (range 6 to 10 mm). The color
ow regurgitant jet was large, eccentric, and extending into
he inferior vena cava (Fig. 2). Pulsed Doppler study showed
rank systolic blood flow reversal inside the inferior vena
ava. Right ventriculography confirmed these findings by
howing opacification of the inferior vena cava by the
egurgitation jet (data not shown).
The metallic frame of the BP being radio-opaque, the
arget site of the VS implantation was therefore easily
dentified. Under fluoroscopic guidance, the VS was prop-
rly positioned inside the BP in all sheep. To evaluate the
ffectiveness of the delivery system, the VS was deliberately
alpositioned inside the BP (Fig. 3). It was then very easy
o correct its position using the compression-relaxation tech-
ique mentioned above (Fig. 3). Deployment of the VS in its
orrect and final position took no more than 2 min. During
hese maneuvers, a transient and mild decrease in systolic
lood pressure (20 mm Hg in all sheep) was observed.stent. (Top, left) The stent has been compressed by exerting traction on
Bottom) The 2 sutures are proximally connected to a handle.
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October 3, 2006:1365–8 A Repositionable Valved StentUnrestricted movement of the VS leaflets was easily
bserved with epicardial bi-dimensional echocardiography.
here was neither residual tricuspid regurgitation nor
eriprosthetic leak in any case (Fig. 2). Median transvalvular
radient was 7 mm Hg (range 6 to 8 mm Hg).
At final analysis of the explanted hearts, all of the VS
ere in good position (Fig. 3). Leaflets of the VS were
igure 2. Echocardiographic color Doppler study before and after endovas
xtending into the inferior vena cava (IVC). (Right) Absence of any tricu
igure 3. Representation of valved stent repositioning. (Top, left) The
ioprosthesis. (Top, right) Recompression of the valved stent. (Bottom,
Bottom, right) Right lateral view of the heart (the right atrium and the anterior p
f the valved stented inside the failed bioprosthesis.erfectly mobile without any evidence of macroscopic injury.
nchorage of the VS inside the BP appeared to be firm.
ISCUSSION
ith the extension of the indication of bioprosthetic VR
nd the ageing of the population, cardiologists and sur-
alve replacement of a failed bioprosthesis. (Left) Tricuspid regurgitant jet
egurgitation after valved stent delivery. RA  right atrium.
d stent has been voluntarily misplaced too proximally inside the failed
The valved stent has been ultimately delivered in an adequate position.cular vvalve
left)art of the right ventricle have been resected) showing excellent positioning
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A Repositionable Valved Stent October 3, 2006:1365–8eons will certainly face more and more cases of SVD.
esides being far less invasive, endovascular replacement
f deteriorated BP should theoretically reduce the oper-
tive mortality by preventing complications of repeat
eart dissection and the deleterious effects of cardiopul-
onary bypass and myocardial ischemia caused by aortic
ross-clamping. This should also imply a dramatic reduc-
ion of hospital costs.
Regurgitating forms of SVD of BP are easily accessible
o an endovascular treatment. The actual self-expandable
tents develop a satisfactory radial force permitting a firm
nchorage of the VS inside a BP. However, in case of severely
alcified BP, a balloon predilation of the BP might be
ecessary.
Several clinical or experimental observations have re-
orted a number of fatal accidents caused by poor position-
ng of a VS (3,6). To the best of our knowledge, none of the
S reported in the literature offers the possibility to be
eadjusted after full deployment. The delivery device we
ested permitted the reversibility of the VS positioning as
any times as needed before the final release. This relied on
simple maneuver (compression-relaxation of the VS) that
ould be performed by 1 operator only.
The present delivery system offers other advantages.
ounting of the VS onto its delivery catheter is greatly
acilitated by the traction on the encircling sutures, which
ould compress the valve. Thus, there is no need for any
rimping device, as is the case for some other VS models.
o achieve adequate positioning of the VS, right ventricular
acing or use of extracorporeal circulation during VS deliv-ry has been recommended by others. With the present
evice, these potentially deleterious strategies are likely to be
nnecessary, as was the case in our experimental study.
In conclusion, endovascular VR was easily performed in
heep with a failed tricuspid BP. The delivery catheter
llowed adequate repositioning of our fully deployed VS
efore its definitive release. One may anticipate that the
afety improvement conferred by this new technology will
ertainly favor the development of percutaneous VR in
linical practice.
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